Biomarkers in Acute Myeloid Leukemia: Leveraging Next Generation Sequencing Data for Optimal Therapeutic Strategies

Biomarkers in Acute Myeloid Leukemia: Leveraging Next Generation Sequencing Data for Optimal Therapeutic Strategies

Next generation sequencing (NGS) is routinely used for mutation profiling of acute myeloid leukemia. The extensive application of NGS in hematologic malignancies, and its significant association with the outcomes in multiple large cohorts constituted a proof of concept that AML phenotype is driven b...

Full description

Bibliographic Details
Main Authors: Hanadi El Achi, Rashmi Kanagal-Shamanna
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Oncology
Subjects:
AML
acute myeloid leukemia
next generation sequencing
actionable mutations
targeted therapy
FDA
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.748250/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.748250/full

Similar Items